Why Are Intricon Shares Surging Monday

Altaris Capital Partners LLC will acquire Implantable device maker Intricon Corporation IIN for $24.25 per share in a transaction that values Intricon at an equity value of approximately $241 million

  • The purchase price represents a premium of approximately 39% to Intricon's closing stock price on February 25.
  • Intricon expects to hold a Special Meeting of Shareholders to consider and vote on the proposed merger and the merger agreement.
  • "We are excited to enter into this transaction with Altaris, which will deliver a compelling valuation to our shareholders and enable us to accelerate the advancement of our joint development manufacturing capabilities in micro medical technology across a broad range of high growth markets," said Scott Longval, President and CEO.
  • Price Action: IIN shares are up 37.3% at $23.93 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: M&ANewsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!